All Updates

All Updates

icon
Filter
Partnerships
XyloCor Therapeutics and SmartWise partner to advance gene therapies for cardiovascular disease
Cell & Gene Therapy
Jul 10, 2024
This week:
Partnerships
Sheeva.AI and P97 Networks partner for in-car payment solutions at fuel stations
Auto Tech
Today
Product updates
Food Cycle Science launches 'Food Cycler Eco 3,' a household food waste processing bin
Food Waste
Yesterday
Partnerships
Von Holzhausen and Herman Miller partner to launch plant-based leather Eames Chair
Bio-based Materials
Yesterday
Partnerships
Volvo Cars partners with Beijing Shougang and Zhejiang Yiyun for automotive steel recycling
Waste Recovery & Management Tech
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Alternative Energy
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
Pet Care Tech
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
InsurTech: Personal Lines
Yesterday
M&A
Applied Systems acquires Planck for undisclosed sum to expand AI capabilities
InsurTech: Infrastructure
Yesterday
Product updates
Monzo launches pension consolidation product
Neobanks
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

Jul 10, 2024

XyloCor Therapeutics and SmartWise partner to advance gene therapies for cardiovascular disease

Partnerships

  • XyloCor Therapeutics has entered into a licensing agreement with SmartWise, a subsidiary of SmartCella Holding AB, giving XyloCor access to SmartWise's proprietary Extroducer Infusion Catheter System for cardiovascular treatment. The total deal value and mid-single-digit royalties are approximately USD 130 million.

  • The agreement will allow the use of the Extroducer novel endovascular device to deliver XyloCor’s top gene therapy candidate, XC001, directly to the heart less invasively, reducing possible surgical complications. The therapy aims to decrease the ischemic load by creating new blood vessels to improve blood flow in heart patients suffering from refractory angina.

  • XyloCor Therapeutics is a biopharmaceutical company specializing in gene therapy for cardiovascular disease, particularly advanced coronary artery disease. Its lead product candidate, XC001 (encoberminogene rezmadenovec), is a single-dose gene therapy currently in clinical development for treating refractory angina, which is a condition characterized by chronic chest pain due to insufficient blood flow to the heart. XyloCor also has a preclinical candidate, XC002, who treats heart attack-related cardiac tissue damage​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.